FibroScan services encompass a comprehensive range of liver health assessments, including measuring liver stiffness to diagnose and stage fibrosis and cirrhosis, and evaluating liver fat content through Controlled Attenuation Parameter (CAP) for conditions like non-alcoholic fatty liver disease (NAFLD). These services are crucial for regular screening programs targeting at-risk populations, such as those with chronic hepatitis, obesity, or a history of alcohol abuse. FibroScan is also integral to ongoing monitoring and follow-up, enabling healthcare providers to track disease progression and treatment response over time. FibroScan is used in pre- and post-liver transplant evaluations and in clinical research to assess the efficacy of new treatments, making it an invaluable tool in both clinical and research settings.